DexCom, Inc. $DXCM Shares Purchased by Groupe la Francaise

Key Points

• Groupe la Francaise increased its stake in DexCom, Inc. by 8.8% during Q1, holding a total of 40,846 shares valued at approximately $2.84 million.
• Several analysts have issued buy ratings on DexCom shares, with price targets ranging from $100.00 to $106.00, indicating a consensus rating of "Moderate Buy" and a target price of $99.89.
• DexCom reported $1.16 billion in revenue for the last quarter, exceeding analyst expectations, and had an earnings per share of $0.48, signaling a 15.2% year-over-year revenue growth.

Groupe la Francaise lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,846 shares of the medical device company's stock after acquiring an additional 3,288 shares during the period. Groupe la Francaise's holdings in DexCom were worth $2,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Horizon Investments LLC grew its position in DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after purchasing an additional 123 shares during the period. Nia Impact Advisors LLC grew its position in DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the period. Wedbush Securities Inc. grew its position in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares during the period. Argonautica Private Wealth Management Inc. grew its position in DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares during the period. Finally, Trivium Point Advisory LLC grew its position in DexCom by 6.1% during the 1st quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company's stock worth $236,000 after purchasing an additional 200 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on DXCM shares. Truist Financial started coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $106.00 price target on shares of DexCom in a research report on Friday, August 1st. Argus started coverage on DexCom in a research report on Thursday. They set a "buy" rating and a $100.00 price target on the stock. Finally, UBS Group increased their price target on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president directly owned 109,621 shares in the company, valued at $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,906 shares of company stock valued at $1,832,451. 0.32% of the stock is owned by corporate insiders.

DexCom Trading Up 2.0%

DXCM stock opened at $82.26 on Friday. The company's 50-day simple moving average is $82.81 and its 200-day simple moving average is $79.83. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The firm has a market cap of $32.26 billion, a P/E ratio of 57.13, a PEG ratio of 1.72 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company posted $0.43 EPS. The company's revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.